Ottumwa council approves roads projects on Mary, Washington streets
OTTUMWA — When it comes to streets, the money doesn't go very far, councilmember Cara Galloway noted Tuesday as the Ottumwa City Council approved two street reconstruction projects.
Between the two projects, costs are expected to exceed $3.5 million total. That cost will cover new pavement, a new turn lane, and work to underground utilities on Mary and Washington streets. Ultimately, the work will cover less than five city blocks in all.
"I think it's important for the public to understand that [the public works department] is working to fix roads, fix our sewers, but our money only goes so far," Galloway said.
The council voted to accept the lowest received bid from Jones Contracting out of West Point related to the Mary Street reconstruction project, which came in about $600,000 under the engineer's estimate.
"[The] price came in pretty good, I think a lot of the COVID price inflation is easing," city engineer Phillip Burgmeier said.
The total contract award was for $2.7 million. Of that, $2.1 million will be paid from a state grant program to cover the street itself. For efficiency, the remainder of the contract will go toward replacing water mains and performing sewer maintenance where needed.
Above ground, the project will reconstruct Mary Street from Ferry Street to Shaul Avenue, while also replacing sidewalks to ADA standards, and adding a left turn lane at the Ferry Street intersection to help with school traffic.
In all, it will replace 12,600 square yards of pavement and adding 650 feet of sidewalk.
"There's full depth concrete replacement," Burgmeier said. "So hopefully it lasts longer than the first time it was paved."
The council approved plans for a reconstruction of Washington Street as well, which will go to bidding. It's expected the contract will be awarded at the council's meeting on May 6.
The project will be a full pavement reconstruction on Washington Street from the south side of the Fourth Street intersection to 100 feet north of Fifth Street. A new sanitary and separated storm sewer system will be installed underneath the pavement.
It's estimated to cost $794,661, with Ottumwa Water Works contributing $72,000 of that. That covers about 3,000 square yards of pavement.
The work schedule for both projects is planned for after the current school year ends and before the next year begins.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Ramey v. Penn State University: Class action lawsuit payments distributed to students
(WHTM) – Penn State University students who were enrolled in classes at the start of the COVID-19 pandemic are now receiving part of a $17 million class action settlement. On March 16, 2020, the university moved to 'remote instruction' due to the outbreak of COVID-19. Years later, a class action lawsuit was brought on behalf of those who paid tuition and/or fees for the Spring 2020 semester and registered for a class. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now The lawsuit was brought forward with allegations of a breach of contract by the university for not providing the services promised with tuition and fees. The university denied the claims asserted against it and agreed to the $17 million settlement for students who opted in to the lawsuit, known as 'Ramey et al. v. The Pennsylvania State University.' A court granted final approval of the settlement on February 18, 2025, and the deadline to file a claim has since passed. According to the Penn State Tuition Refund Settlement website, payments to eligible class members were sent on June 5, 2025. The website says those who opted to receive payments should have received notification of their award via email and should expect a check in the mail. Payments were automatically sent to the recipients' 'last known permanent postal address on file with Penn State,' according to the settlement website. The deadline to change that address or type of payment has also passed. Of the $17 million in settlement funds, the final judgment awarded attorneys' fees of $5,666,100, deducted litigation expenses worth $17,990.94, and made a $15,000 award for the individuals who initiated the lawsuit. The remaining portion of the money (approximately $11,300,909) was designated as the 'Net Settlement Fund.' Students eligible for payments 'who withdrew for medical reasons from Penn State after March 16, 2020, but before the conclusion of the Spring 2020 semester, and received a refund of tuition,' will receive $50 from the Net Settlement Fund. The remaining funds were then 'distributed equally to all other Settlement Class Members.' Eligible students included those attending branch campuses at the time of the shutdown, according to the settlement. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 hours ago
- Yahoo
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. COVID vaccine maker BioNTech is buying rival CureVac, announcing Thursday an all-stock deal weeks before the two companies were due to face off in a German court over potentially billions of dollars worth of royalties related to intellectual property on messenger RNA drugs. Per deal terms, each CureVac share will be exchanged for about $5.46 worth of BioNTech's U.S.-listed shares, valuing the company at $1.25 billion. Upon the deal's close, CureVac shareholders will own between 4% and 6% of BioNTech. In the early days of the COVID-19 pandemic, BioNTech and CureVac were among the companies racing to develop the first coronavirus vaccines. BioNTech, however, partnered with Pfizer and won approval of the first COVID-19 shot, while CureVac's program never made it to market. The two companies have since been embroiled in patent litigation. CureVac was a leading candidate to develop the first COVID-19 vaccine, launching rumors, later denied, that the U.S. government might even buy the company or its research. But while BioNTech and fellow mRNA drugmaker Moderna succeeded in making vaccines that saved millions of lives and earned billions of dollars in revenue, CureVac fell short. Its initial project wasn't effective enough at preventing sickness, prompting it to scrap development. A year later, CureVac sued BioNTech, claiming it infringed four patents. CureVac has since changed course, selling off most rights to influenza and COVID-19 vaccines to partner GSK and focusing on cancer instead. But its legal spat with BioNTech has lingered. The European Patent Office had upheld two CureVac patents, and a trial in a Dusseldorf regional court was set on July 1 to determine if BioNTech had infringed on them. A separate trial in the U.S. was scheduled to begin Sept. 8 in Virginia. Some Wall Street analysts, as a result, speculated that BioNTech's primary purpose is buying CureVac is to sidestep the risk of a loss in court. A single-digit percentage royalty awarded to CureVac could've cost BioNTech as much as $3 billion, Evercore ISI analyst Umer Raffat wrote in a note to clients. 'It seems to us that [BioNTech] assessed the cost of a cash settlement as substantially greater than the cost of buying [CureVac] outright,' Raffat wrote. The deal could also help BioNTech further its oncology ambitions. Like CureVac, BioNTech has made cancer research a top priority. It's invested in a variety of programs, from cell therapies to mRNA vaccines and a coveted type of bispecific antibody. Some are in advanced testing. CureVac's cancer vaccines are in earlier phases of development. A brain cancer shot has delivered early clinical data, while a lung cancer immunotherapy was cleared in April for human testing. The deal should help CureVac because of 'the early stage of the oncology pipeline and the need for a development partner to effectively compete in personalized cancer vaccines – which [BioNTech] is well positioned to execute,' wrote Leerink Partners analyst Mani Foroohar. Raffat, of Evercore ISI, however, wrote that the deal ascribes 'very little value' to CureVac's pipeline. Recommended Reading Recursion to acquire two Canadian drug discovery startups Sign in to access your portfolio
Chicago Tribune
3 hours ago
- Chicago Tribune
Lake County board member praises $9.1 million investment into bike path
Lake County approved a $9.1 million contract to pave just over 12 miles of the Robert McClory Bike Path, with additional future crossing improvements planned in the future. The 25-mile trail, named after the eponymous Illinois State Representative in the late 1990s, was formerly a rail line between Chicago and Milwaukee. The sections in question run from Russell Road to Broadway Avenue and from Old Elm Road to Vine Avenue. Work includes paving the gravel path with asphalt, resurfacing existing asphalt, concrete repairs, ADA upgrades, drainage improvements and increased local connectivity, according to county documents. District 15 County Board Member Jennifer Clark lauded the benefits the work, which is planned to begin this summer and be completed later this year, will bring to the trail. Paving will reduce stormwater issues, she said. 'As anyone who knows who has ridden that trail, parts of the gravel tend to wash out during storms and over the winter due to snow and ice,' Clark said. 'This will ensure a smooth ride for everyone.' The county has also worked with neighbors and local municipalities to identify connecting trails to the path, some of them unofficial, to help improve accessibility, Clark said. There are also plans, potentially for next summer, to improve several crossings along the path. Clark said the work is part of a broader effort by the county to focus on improving non-motorized connections, primarily to address safety concerns over an uptick in injuries and fatalities relating to pedestrians and bicycle riders. 'We really have changed our focus from only looking at bike paths or sidewalk improvements for select areas of Lake County to now we are doing it standard with everything,' Clark said. 'Every time a road or an area comes up for a rebuild, we look at improving existing facilities or adding new ones.' The work has recreational and resident enjoyment benefits as well, and can help reduce commuter traffic, she said. 'I can't tell you how many people have told me they moved to Lake County because of the bike trails and the forests,' Clark said. Lake County has over 550 miles of trails and bikeways, according to the Lake County Department of Transportation.
